SK pharmteco Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing
- SK pharmteco will invest over $200 million across five years to expand U.S. development labs, GMP manufacturing capacity for small molecules and APIs, and peptide purification with kilo-scale GMP capability operational by late 2026.
- The investment includes new development laboratories, advanced liquid chromatography systems, modernized GMP suites, and green-technology infrastructure upgrades expected to create 100 long-term skilled jobs domestically.
- Expansion complements SK pharmteco's recent opening of two advanced manufacturing facilities in Ireland for large-scale commercial small molecules and ultra-high-potency active pharmaceutical ingredients.
Operational Impact
SK pharmteco's new U.S. GMP peptide kilo-scale capacity (late 2026) and expanded small-molecule manufacturing suites reduce regional supply risk for CDMO customers seeking domestic, sustainable API and peptide sourcing through commercial scale.
Source: Contract Pharma Breaking News RSS
Piramal Pharma Solutions Secures $1.75M Ontario Grant for Aurora API Site Expansion
- Piramal Pharma Solutions received $1.75M from Ontario's Life Sciences Scale-Up Fund to upgrade its Aurora, Canada drug substance manufacturing facility.
- PPS is co-investing $5.31M total to enhance R&D, clinical API production, and commercial drug-substance capacity while creating 12 new jobs and protecting 183 existing roles.
- Infrastructure upgrades will focus on sustainability, operational efficiency, and site modernization to strengthen domestic API production and manufacturing capabilities.
Operational Impact
Piramal's Aurora facility upgrade adds North American API manufacturing capacity for clinical and commercial supply, reinforcing domestic sourcing options for sponsors seeking Canadian-based drug-substance CDMO partners.
Source: PharmaSource RSS
Axplora Advances Exatecan GMP Supply Route for ADC Developers
- Axplora completed first R&D batches of Exatecan and produced gram quantities as part of its Axotecan project to establish independent European supply.
- Company targets validation batches by end of 2026 and initial GMP supply in late 2027, subject to technical, quality, and regulatory milestones.
- Initiative addresses ADC developer demand for supply diversity, consistent quality, and shorter lead times for critical payload-linker materials.
Operational Impact
Axplora's Exatecan GMP supply route entering validation phase by end of 2026 provides ADC developers with a European alternative to existing suppliers, reducing single-source risk for a critical payload material.
Source: PharmaSource RSS
Genezen to Manufacture AAV9 Gene Therapy for N-of-1 ARCA2 Trial
- Genezen will provide viral vector manufacturing and analytical capabilities for an AAV9 gene therapy targeting autosomal recessive spinocerebellar ataxia-2 (ARCA2), an ultra-rare disorder affecting ~25 patients worldwide.
- The N-of-1 clinical trial, developed with University of Missouri's NextGen Precision Health initiative, leverages Genezen's accelerated manufacturing and release timeline expertise for small patient population programs.
Operational Impact
Genezen's N-of-1 ARCA2 program showcases CDMO differentiation in ultra-rare gene therapy manufacturing where accelerated timelines and in-house analytical capabilities enable clinical trials for patient populations too small for traditional development pathways.
Source: PharmaSource RSS
References
- Contract Pharma Breaking News RSS — SK pharmteco Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing
- PharmaSource RSS — Piramal Pharma Solutions Secures $1.75M Ontario Grant for Aurora API Site Expansion
- PharmaSource RSS — Axplora Advances Exatecan GMP Supply Route for ADC Developers
- PharmaSource RSS — Genezen to Manufacture AAV9 Gene Therapy for N-of-1 ARCA2 Trial